Advancements in Dermatology: A Weekly Review
Dermatologia e Venerologia
Autoimmunity, Dermatology Breakthroughs, and STI Updates
This week's episode covers autoimmune conditions in Down syndrome, new psoriasis treatments, updated STI guidelines, and the latest in atopic dermatitis management. We discuss key findings from recent studies and their clinical implications.
Bibliography
1. Down Syndrome and Autoimmune Disease.
Authors: Hom B, Boyd NK, Vogel BN, et al.
Journal: Clinical reviews in allergy & immunology, 2024 Jun
PMID: 38913142
DOI: 10.1007/s12016-024-08996-2
2. IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade.
Authors: Ayers M, Lunceford J, Nebozhyn M, et al.
Journal: The Journal of clinical investigation, 2017 Aug 1
PMID: 28650338
DOI: 10.1172/JCI91190
3. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial.
Authors: Armstrong AW, Gooderham M, Warren RB, et al.
Journal: Journal of the American Academy of Dermatology, 2023 Jan
PMID: 35820547
DOI: 10.1016/j.jaad.2022.07.002
4. Phase II Randomized Trial of Transoral Surgery and Low-Dose Intensity Modulated Radiation Therapy in Resectable p16+ Locally Advanced Oropharynx Cancer: An ECOG-ACRIN Cancer Research Group Trial (E3311).
Authors: Ferris RL, Flamand Y, Weinstein GS, et al.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2022 Jan 10
PMID: 34699271
DOI: 10.1200/JCO.21.01752
5. Diagnosis and Management of Trichomonas vaginalis: Summary of Evidence Reviewed for the 2021 Centers for Disease Control and Prevention Sexually Transmitted Infections Treatment Guidelines.
Authors: Kissinger PJ, Gaydos CA, Seña AC, et al.
Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2022 Apr 13
PMID: 35416973
DOI: 10.1093/cid/ciac030
6. Management of patients with hidradenitis suppurativa.
Authors: Martorell A, Caballero A, González Lama Y, et al.
Journal: Actas dermo-sifiliograficas, 2016 Sep
PMID: 28081768
DOI: 10.1016/S0001-7310(17)30007-8
7. Systemic treatments for atopic dermatitis (eczema): Systematic review and network meta-analysis of randomized trials.
Authors: Chu AWL, Wong MM, Rayner DG, et al.
Journal: The Journal of allergy and clinical immunology, 2023 Dec
PMID: 37678577
DOI: 10.1016/j.jaci.2023.08.029
8. Guselkumab for Moderate to Severe Scalp Psoriasis Across All Skin Tones: Cohort B of the VISIBLE Randomized Clinical Trial.
Authors: McMichael A, Shahriari M, Stein Gold L, et al.
Journal: JAMA dermatology, 2025 Sep 1
PMID: 40560554
DOI: 10.1001/jamadermatol.2025.1849
9. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update.
Authors: Gossec L, Kerschbaumer A, Ferreira RJO, et al.
Journal: Annals of the rheumatic diseases, 2024 May 15
PMID: 38499325
DOI: 10.1136/ard-2024-225531
Authors: Hom B, Boyd NK, Vogel BN, et al.
Journal: Clinical reviews in allergy & immunology, 2024 Jun
PMID: 38913142
DOI: 10.1007/s12016-024-08996-2
2. IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade.
Authors: Ayers M, Lunceford J, Nebozhyn M, et al.
Journal: The Journal of clinical investigation, 2017 Aug 1
PMID: 28650338
DOI: 10.1172/JCI91190
3. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial.
Authors: Armstrong AW, Gooderham M, Warren RB, et al.
Journal: Journal of the American Academy of Dermatology, 2023 Jan
PMID: 35820547
DOI: 10.1016/j.jaad.2022.07.002
4. Phase II Randomized Trial of Transoral Surgery and Low-Dose Intensity Modulated Radiation Therapy in Resectable p16+ Locally Advanced Oropharynx Cancer: An ECOG-ACRIN Cancer Research Group Trial (E3311).
Authors: Ferris RL, Flamand Y, Weinstein GS, et al.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2022 Jan 10
PMID: 34699271
DOI: 10.1200/JCO.21.01752
5. Diagnosis and Management of Trichomonas vaginalis: Summary of Evidence Reviewed for the 2021 Centers for Disease Control and Prevention Sexually Transmitted Infections Treatment Guidelines.
Authors: Kissinger PJ, Gaydos CA, Seña AC, et al.
Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2022 Apr 13
PMID: 35416973
DOI: 10.1093/cid/ciac030
6. Management of patients with hidradenitis suppurativa.
Authors: Martorell A, Caballero A, González Lama Y, et al.
Journal: Actas dermo-sifiliograficas, 2016 Sep
PMID: 28081768
DOI: 10.1016/S0001-7310(17)30007-8
7. Systemic treatments for atopic dermatitis (eczema): Systematic review and network meta-analysis of randomized trials.
Authors: Chu AWL, Wong MM, Rayner DG, et al.
Journal: The Journal of allergy and clinical immunology, 2023 Dec
PMID: 37678577
DOI: 10.1016/j.jaci.2023.08.029
8. Guselkumab for Moderate to Severe Scalp Psoriasis Across All Skin Tones: Cohort B of the VISIBLE Randomized Clinical Trial.
Authors: McMichael A, Shahriari M, Stein Gold L, et al.
Journal: JAMA dermatology, 2025 Sep 1
PMID: 40560554
DOI: 10.1001/jamadermatol.2025.1849
9. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update.
Authors: Gossec L, Kerschbaumer A, Ferreira RJO, et al.
Journal: Annals of the rheumatic diseases, 2024 May 15
PMID: 38499325
DOI: 10.1136/ard-2024-225531
